....mark my words BTX will double in three months time.
KALAMAZOO, MI — A Kalamazoo man who became paralyzed in an accident eight months after his brother became paralyzed in a separate accident is participating in a clinical trial that may give him back the use of his arms.
"My hope is that I can use my hands," said Adam Chaffee, 23, who was injured last month after a friend playfully pushed him off a dock. "That's my main hope, my arms and my hands. I can move my arms, and I can move my wrists, but I can't move my fingers."
Chaffee is at Rush University Medical Center in Chicago, where on Thursday he underwent a stem-cell treatment as part of a clinical trial. He fit the bill for ideal candidates: patients ages 18 to 65 who recently experienced a cervical spinal cord injury that caused partial or total paralysis of their arms, legs and torso. The procedure must happen between 14 to 30 days post-injury.
Asterias Biotherapeutics, a San Francisco Bay-area biotechnology company, develops the cells and is sponsoring the study. That means it is free for Chaffee to participate.
Good insight, amazing all that has gotten done in eight years with no revenues, just goes to show how much investors and partners believe!
Another low hanging fruit besides PanC-DX is Biotimes cosmetic surgery product Renevia. Product being tested in Europes largest cosmetic surgery hospital in Spain, uses adipose cells, product final testing by years end. Approval could mean that Biotime's next-gen plastic surgery procedures become standard procedure in EU.
Big time investors to sink teeth into BTX in 2016!
Have you ever heard of a company with over 700 cutting edge patents?...Well the average investor is about to!
Ah the old RS fear gong has sounded. Not going to happen here. we own 68% of AST who will announce positive cancer vaccine clinical trial results next year and BTX to announce big time contracts for PanC-DX.
Check your pulse!
Ok bb, talk is cheap....but let me ask you. If you get cancer next year and have to get answers right away, would you get PanC-DX test for $500 or wait for older products to tell you the results next week for $5000?
Don't be fooled, stock price reflects lack of revenues. Cancer diagnostic products released by years end. These lung, bladder and breast cancer tests will be huge money makers since they are the next gen industry standard and they're partner Weill Cornell is one of the top hospitals in the country.
Well Summer is coming to a close, IPO likley TBA in September. I would think Biotime's ownership ratio in OncoCyte should be similar to AST's 68%.
Good time to buy in....CHEAP-CHEAP-CHEAP!!!
GE as many know initially was working with hESC's from Geron ip, then Ips cells from Cellular Dynamics, and now back to hESC with BTX. HESC's look to be the gold standard.
Looked at the 5 yr. chart and seems your on the ball. ISSCR is huge and GE/ESI should have something concrete to present since they formed a partnership 7 mo ago.
June 24-27, 2015
International Society for Stem Cell
Research (ISSCR) Annual Meeting
ESI BIO – A Division of BioTime, Inc.
thanks for the insight clone. 2016 will be very exciting and $20 is very likely with GE products as well as the bladder, breast and lung cancer tests on the market.
$20 for mid 2016 and higher as the year goes on.
MRNA one of the few RNAI companies yet to propel above $2 range. I bought in after several recent key milestones. SMARTICLES continued clinical success. There delivery of next-gen drugs(RNAI/stem cells) is very lucrative and MRNA seems to have a unique and important platform with SMARTICLES.
I also think the recent securing of key RNAi ip is key to MRNA's success and would think this would soon lead to major partnerships, mergers or a possible buyout. Lastly I thought Marina's new anti-tumor/white blood cell news sounded interesting.
My 2 cents
August and Sept pop with investors buying in a month or two before these blockbuster products in 4th Quarter. Until then guessing it will coast. 4.50 seems like the bottom considering their subsidiary AST is $12.